BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/8/2022 12:06:56 PM | Browse: 724 | Download: 1732
 |
Received |
|
2021-12-06 13:56 |
|
Peer-Review Started |
|
2021-12-06 13:58 |
|
First Decision by Editorial Office Director |
|
2022-01-18 01:17 |
|
Return for Revision |
|
2022-01-18 01:17 |
|
Revised |
|
2022-01-26 15:00 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-02-24 06:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-02-27 19:07 |
|
Articles in Press |
|
2022-02-27 19:07 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-03-27 11:44 |
|
Publish the Manuscript Online |
|
2022-04-08 12:06 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hang-Ping Wei, Jie Mao and Zhu-Liang Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhu-Liang Hu, Doctor, Deputy Director, Department of Medical Oncology, Dongyang Hospital Affiliated to Wenzhou Medical University, No. 60 West Wuning Road, Dongyang 322100, Zhejiang Province, China. applewhp1988@163.com |
| Key Words |
Apatinib; Renal cell carcinoma; Targeted therapy; Palliative treatment; Case report |
| Core Tip |
Apatinib, an orally bioavailable small-molecule receptor tyrosine kinase inhibitor, is typically used in the treatment of partial solid tumours. Here, we report a case of advanced renal cell carcinoma (RCC) with multiple metastases (Stage IV) in a 48-year-old man with an extremely poor general status (Karnofsky 30%). Due to his intolerance to pazopanib (patient developed oral mucositis), we attempted targeted treatment with apatinib, at a dose of 250 mg once daily (from April 2018). This led to an excellent recovery response, realising an approximately 32 mo progression-free survival. This case suggests that apatinib, like other multi-target drugs, may be used as a first-line therapeutic treatment for advanced RCC. |
| Publish Date |
2022-04-08 12:06 |
| Citation |
Wei HP, Mao J, Hu ZL. Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. World J Clin Cases 2022; 10(11): 3593-3600
|
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i11/3593.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i11.3593 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
